Marsh D F, Hodkinson B
Department of Anaesthesia, Queen Alexandra Hospital, Portsmouth, UK.
Anaesthesia. 2009 Mar;64(3):301-8. doi: 10.1111/j.1365-2044.2008.05731.x.
Remifentanil is a synthetic opioid, first introduced into clinical practice in 1996. Its unique pharmacokinetic profile has resulted in a gradual increase in its popularity in paediatric anaesthesia. It is an opioid of high potency and rapid clearance, consequently lacking problems of accumulation. These characteristics give it a high degree of predictability and it has become an attractive choice for a wide variety of anaesthetic challenges, from premature neonates to the elderly. Neonates and infants have a higher clearance than older children and, as a result, remifentanil has additional benefits in this group. Remifentanil can be described as the only consistently predictable opioid in paediatric practice.
瑞芬太尼是一种合成阿片类药物,于1996年首次应用于临床实践。其独特的药代动力学特性使其在小儿麻醉中的应用逐渐增多。它是一种高效且清除迅速的阿片类药物,因此不存在蓄积问题。这些特性赋予了它高度的可预测性,使其成为应对从早产儿到老年人等各种麻醉挑战的有吸引力的选择。新生儿和婴儿的清除率高于大龄儿童,因此瑞芬太尼在这一群体中具有额外的优势。瑞芬太尼可被描述为小儿麻醉实践中唯一始终具有可预测性的阿片类药物。